Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- Alzheimerâ€™s disease
- Diabetes Treatment
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 63131
IPSCIO Record ID: 2512
IPSCIO Record ID: 359135
IPSCIO Record ID: 1334
The Licensee is solely responsible for the costs and development of KB001-A for pneumonia prevention and other hospital indications. We are currently planning a Phase 2 trial in CF.
IPSCIO Record ID: 125020
IPSCIO Record ID: 27942
For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.
IPSCIO Record ID: 238987
The Canadian Licensor grants to Licensee an exclusive sublicense, even as against the Licensor, under the Patent Rights to develop and have developed, market and have marketed, sell and have sold, distribute and have distributed, and manufacture and have manufactured, the Licensed Products in the Territory, said license to include the right to further sub-license.
Licensed Product shall mean anhydrovinblastine sulfate (AVLB), with the chemical name 3 ,4 – dehydrovinblastine sulphate and molecular formula C4Jls~40s-H2SO4â€¢.
KRX-0403 is a novel spindle poison in the vinca alkaloid class of drugs. Derived from the periwinkle plant, the family of vinca alkaloids and the mechanistically similar family of taxanes include some of the most successful cancer drugs ever developed, including NavelbineÂ®, TaxolÂ® and TaxotereÂ®. Although these agents have been widely prescribed, they can be very toxic and may cause varying degrees of neurotoxicity and/or bone marrow suppression. We believe that an equally or more effective but less toxic therapy would satisfy a substantial need for these patients. In a number of pre-clinical animal studies of human cancers, including non-small cell lung cancer, KRX-0403 demonstrated greater anti-cancer activity and lower toxicity than currently marketed vinca alkaloids. In a Phase I clinical trial designed to evaluate the safety, toxicity profile and pharmacokinetics of KRX-0403 in patients with different tumor types, including lung cancer, breast cancer, sarcoma and colon cancer, KRX-0403 was demonstrated to be safe in humans with reversible and manageable toxicities. We believe KRX-0403 may have utility in the treatment of breast, lung and other forms of cancer. We plan to conduct additional dosing clinical trials for KRX-0403.
IPSCIO Record ID: 93480
The Cell-in-a-BoxÂ® technology, is a means to protect, isolate, store and transport living cells.
Bac-in-a-Box involves the technology which allows living cells to be encapsulated into bio-inert polymer beads. This technology allows both living eukaryotic (e.g. stem cells) and bacterial cells (e.g. probiotics) to be encapsulated in order to protect, store, isolate and transport them.
IPSCIO Record ID: 260
Under the Terms of Agreement, Licensee and Licensor have agreed to enter into a Collaboration Agreement under which the Licensor will grant the Licensee exclusive rights and Licenses under certain Licensor patent rights, pre-clinical data and clinical data from clinical trials of TSO in Crohnâ€™s disease, including an ongoing Phase II clinical trial, for use in North America, South America and Japan.
The German Licensor will grant the Licensee exclusive rights and Licenses to Company data from planned clinical trials of TSO in Crohnâ€™s disease for use in Europe.
A Steering Committee comprised of the Licensee, Licensor and OvaMed representatives will oversee the development program, under which Coronado each be responsible for clinical testing on approximately 50% of the total number of patients required for regulatory approval of TSO for Crohnâ€™s disease in the United States and Europe.
IPSCIO Record ID: 299281
University also grants the right to enter into sublicensing agreements under the Patent Rights.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.
KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.
IPSCIO Record ID: 28080
IPSCIO Record ID: 310513
Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. T cells recognize antigenic epitopes when they are â€˜presentedâ€™ to them by specific molecules, termed (MHC) on the surface of infected or malignant cells. This interaction activates the T cells, stimulating a multicellular cascade of actions that eliminates the diseased cell and protects against future disease recurrence.
In 2006 Phase I clinical trial was completed of AE37 in breast cancer, including a phase Ib safety and immunology study of AE37 in combination with GM-CSF in 16 breast cancer patients who had completed all first-line therapies and who were disease-free at the time of enrollment to the study (Holmes et al. Results of the first phase I clinical trial of the novel Ii-Key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;263426-33).
The Foundation conducted the study, under the sponsorship of an institute affiliated with the United States Military until the IND #12229 was transferred to the Company, after which Foundation continued trial management on behalf of the Company.
The Foundation is a nonprofit organization dedicated to advancing medicine by administering, managing and supporting preeminent scientific programs.
Licensee is an oncology company focused on the modulation of the immune system to treat cancer and is developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key.